MX2022015524A - Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. - Google Patents

Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.

Info

Publication number
MX2022015524A
MX2022015524A MX2022015524A MX2022015524A MX2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A
Authority
MX
Mexico
Prior art keywords
cyclohexyl
crystalline forms
ylsulfanyl
ureido
thiazol
Prior art date
Application number
MX2022015524A
Other languages
English (en)
Inventor
Jing Teng
Yizheng Cao
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2022015524A publication Critical patent/MX2022015524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente descripción se refiere a a) formas cristalinas de ácido {2-[3-ciclohexil-3-(trans-4- propoxi-ciclohexil)-ureido]-tia zol-5-ilsulfanil}-acético ("Compuesto I "); b) composiciones farmacéuticas, que comprenden una o más formas cristalinas del Compuesto I y, opcionalmente, un portador farmacéuticamente aceptable; c) métodos para tratar un tipo de diabetes mellitus u otros trastornos mediante la administración de una o más formas cristalinas del Compuesto I; y d) métodos para la preparación de formas cristalinas del Compuesto I.
MX2022015524A 2020-06-08 2021-06-07 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. MX2022015524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035994P 2020-06-08 2020-06-08
PCT/US2021/036082 WO2021252309A1 (en) 2020-06-08 2021-06-07 Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof

Publications (1)

Publication Number Publication Date
MX2022015524A true MX2022015524A (es) 2023-03-22

Family

ID=78846441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015524A MX2022015524A (es) 2020-06-08 2021-06-07 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.

Country Status (9)

Country Link
US (1) US20230219910A1 (es)
EP (1) EP4161639A4 (es)
JP (1) JP2023530785A (es)
KR (1) KR20230048501A (es)
CN (1) CN116056760A (es)
AU (1) AU2021289591A1 (es)
CA (1) CA3181665A1 (es)
MX (1) MX2022015524A (es)
WO (1) WO2021252309A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188676A (zh) * 2013-03-04 2015-12-23 Vtv治疗有限责任公司 包括葡糖激酶活化剂的固体组合物及其制备和使用方法
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06007667A (es) * 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
CA2799591C (en) * 2010-05-26 2019-06-11 Transtech Pharma, Inc. Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
KR102371364B1 (ko) * 2012-05-17 2022-03-07 브이티브이 테라퓨틱스 엘엘씨 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물
CN105188676A (zh) * 2013-03-04 2015-12-23 Vtv治疗有限责任公司 包括葡糖激酶活化剂的固体组合物及其制备和使用方法
MX2015011109A (es) * 2013-03-04 2015-11-16 Vtv Therapeutics Llc Composiciones estables de activador de glucoquinasa.
CA3046861A1 (en) * 2016-12-15 2018-06-21 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor

Also Published As

Publication number Publication date
WO2021252309A1 (en) 2021-12-16
US20230219910A1 (en) 2023-07-13
JP2023530785A (ja) 2023-07-19
CA3181665A1 (en) 2021-12-16
CN116056760A (zh) 2023-05-02
EP4161639A4 (en) 2024-01-17
EP4161639A1 (en) 2023-04-12
AU2021289591A1 (en) 2023-01-19
KR20230048501A (ko) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2022015524A (es) Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
BRPI0409109A (pt) novos compostos
WO2003002593A3 (en) Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
JP2005225877A (ja) 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニレン）−１３，１４−ジヒドロ−プロスタグランジンＦ１の使用
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
WO2006048750A3 (en) Novel compounds of substituted and unsubstituted adamantyl amides
ATE416159T1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
HUP0202400A2 (hu) Prosztaglandinszármazékot tartalmazó készítmény külső elválasztási rendellenességek kezelésére
MY174002A (en) Combination theraphy for the treatment of diabetes
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IE43916L (en) Allenic prostaglandins
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
BRPI0316908B8 (pt) preparo de suspensões aquosas estéreis incluindo ingredientes ativos cristalinos micronizados para inalação
MX2023002547A (es) Compuestos novedosos como inhibidor de histona desacetilasa 6 y composicion farmaceutica que comprende los mismos.
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
EP3134393B1 (en) Cyclohexenyl compounds, compositions comprising them and uses thereof
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
EP1374868A4 (en) MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC ISCHEMIC DISEASES
DE2941288A1 (de) Cystein-derivate
MX2023011920A (es) Compuestos de 1,3,4-oxadiazol tiocarbonilo como inhibidores de histona deacetilasa 6, y composicion farmaceutica que los comprende.
IL42787A (en) Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids